CA3048650A1 - Methods of treating bacterial infections - Google Patents

Methods of treating bacterial infections Download PDF

Info

Publication number
CA3048650A1
CA3048650A1 CA3048650A CA3048650A CA3048650A1 CA 3048650 A1 CA3048650 A1 CA 3048650A1 CA 3048650 A CA3048650 A CA 3048650A CA 3048650 A CA3048650 A CA 3048650A CA 3048650 A1 CA3048650 A1 CA 3048650A1
Authority
CA
Canada
Prior art keywords
subject
meropenem
vaborbactam
cuti
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3048650A
Other languages
English (en)
French (fr)
Inventor
Jeffrey S. Loutit
Michael N. Dudley
Elizabeth E. Morgan
Karen FUSARO
David C. Griffith
Olga Lomovskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rempex Pharmaceuticals Inc
Original Assignee
Fusaro Karen
Loutit Jeffrey S
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3048650(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fusaro Karen, Loutit Jeffrey S, Rempex Pharmaceuticals Inc filed Critical Fusaro Karen
Publication of CA3048650A1 publication Critical patent/CA3048650A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3048650A 2017-01-09 2018-01-08 Methods of treating bacterial infections Pending CA3048650A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US62/444,238 2017-01-09
US201762513936P 2017-06-01 2017-06-01
US62/513,936 2017-06-01
PCT/US2018/012839 WO2018129479A1 (en) 2017-01-09 2018-01-08 Methods of treating bacterial infections

Publications (1)

Publication Number Publication Date
CA3048650A1 true CA3048650A1 (en) 2018-07-12

Family

ID=62791302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3048650A Pending CA3048650A1 (en) 2017-01-09 2018-01-08 Methods of treating bacterial infections

Country Status (21)

Country Link
US (1) US12478606B2 (https=)
EP (2) EP3565551B1 (https=)
JP (2) JP7436206B2 (https=)
KR (2) KR102768209B1 (https=)
CN (1) CN110402139A (https=)
AU (1) AU2018205327B2 (https=)
BR (1) BR112019014089A2 (https=)
CA (1) CA3048650A1 (https=)
CL (2) CL2019001918A1 (https=)
CO (1) CO2019008575A2 (https=)
DK (1) DK3565551T3 (https=)
ES (1) ES2979266T3 (https=)
FI (1) FI3565551T3 (https=)
HU (1) HUE066805T2 (https=)
MX (2) MX390529B (https=)
NZ (1) NZ755141A (https=)
PH (1) PH12019501606A1 (https=)
PL (1) PL3565551T3 (https=)
PT (1) PT3565551T (https=)
SG (1) SG11201906226YA (https=)
WO (1) WO2018129479A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法
US11376237B2 (en) 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections
WO2022026993A1 (en) * 2020-07-27 2022-02-03 Northwestern University Antimicrobial choice algorithm for urinary tract infections
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy
CN121419770A (zh) * 2023-05-02 2026-01-27 希普拉有限公司 包含抗细菌剂的药物组合及其组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN105393011A (zh) * 2013-05-15 2016-03-09 舍弗勒技术股份两合公司 减少阻力的离合器板
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法

Also Published As

Publication number Publication date
KR102768209B1 (ko) 2025-02-18
US20190336475A1 (en) 2019-11-07
NZ755141A (en) 2023-01-27
MX2022001704A (es) 2022-03-11
EP3565551A4 (en) 2020-09-23
JP2020504154A (ja) 2020-02-06
SG11201906226YA (en) 2019-08-27
US12478606B2 (en) 2025-11-25
MX390529B (es) 2025-03-20
CL2020001886A1 (es) 2020-12-18
PH12019501606A1 (en) 2020-06-15
PL3565551T3 (pl) 2024-09-23
WO2018129479A1 (en) 2018-07-12
AU2018205327B2 (en) 2023-11-30
CL2019001918A1 (es) 2020-02-14
KR20240133785A (ko) 2024-09-04
CN110402139A (zh) 2019-11-01
BR112019014089A2 (pt) 2020-02-04
JP2023012538A (ja) 2023-01-25
CO2019008575A2 (es) 2019-08-30
FI3565551T3 (fi) 2024-06-18
DK3565551T3 (da) 2024-06-17
ES2979266T3 (es) 2024-09-25
HUE066805T2 (hu) 2024-09-28
AU2018205327A1 (en) 2019-07-25
KR20190104385A (ko) 2019-09-09
EP3565551A1 (en) 2019-11-13
JP7436206B2 (ja) 2024-02-21
MX2019008281A (es) 2019-12-02
PT3565551T (pt) 2024-06-14
EP4212157A1 (en) 2023-07-19
EP3565551B1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
US11007206B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP7245289B2 (ja) 細菌感染症の処置方法
EP3139930B1 (en) Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US12478606B2 (en) Methods of treating bacterial infections
WO2014144295A1 (en) Ceftolozane antibiotic compositions
US9629861B2 (en) Compositions and methods for treating bacterial infections using ceftaroline
HK40097685A (en) Methods of treating bacterial infections with vaborbactam and meropenem
HK40018408B (en) Methods of treating bacterial infections with a combination of vaborbactam and meropenem
HK40018408A (en) Methods of treating bacterial infections with a combination of vaborbactam and meropenem
NZ795891A (en) Methods of treating bacterial infections
HK40051777A (en) Methods of treating bacterial infections
HK1249432B (en) Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240906

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219